Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 May;65(5):654-61.
doi: 10.1136/ard.2005.044958. Epub 2005 Dec 8.

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

J-Y Reginster  1 , S Adami, P Lakatos, M Greenwald, J J Stepan, S L Silverman, C Christiansen, L Rowell, N Mairon, B Bonvoisin, M K Drezner, R Emkey, D Felsenberg, C Cooper, P D Delmas, P D Miller
Affiliations
Clinical Trial

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

J-Y Reginster et al. Ann Rheum Dis. 2006 May.

Erratum in

  • Ann Rheum Dis. 2008 Feb;67(2):280

Abstract

Background: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has been developed to overcome this problem.

Objective: To confirm the 1 year results and provide more extensive safety and tolerability information for once-monthly dosing by a 2 year analysis.

Methods: MOBILE, a randomised, phase III, non-inferiority study, compared the efficacy and safety of once-monthly ibandronate with daily ibandronate, which has previously been shown to reduce vertebral fracture risk in comparison with placebo.

Results: 1609 postmenopausal women were randomised. Substantial increases in lumbar spine bone mineral density (BMD) were seen in all treatment arms: 5.0%, 5.3%, 5.6%, and 6.6% in the daily and once-monthly groups (50 + 50 mg, 100 mg, and 150 mg), respectively. It was confirmed that all once-monthly regimens were at least as effective as daily treatment, and in addition, 150 mg was found to be better (p<0.001). Substantial increases in proximal femur (total hip, femoral neck, trochanter) BMD were seen; 150 mg produced the most pronounced effect (p<0.05 versus daily treatment). Independent of the regimen, most participants (70.5-93.5%) achieved increases above baseline in lumbar spine or total hip BMD, or both. Pronounced decreases in the biochemical marker of bone resorption, sCTX, observed in all arms after 3 months, were maintained throughout. The 150 mg regimen consistently produced greater increases in BMD and sCTX suppression than the 100 mg and daily regimens. Ibandronate was well tolerated, with a similar incidence of adverse events across groups.

Conclusions: Once-monthly oral ibandronate is at least as effective and well tolerated as daily treatment. Once-monthly administration may be more convenient for patients and improve therapeutic adherence, thereby optimising outcomes.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors have received fees or reimbursement from the study sponsors, F Hoffmann‐La Roche Ltd and GlaxoSmithKline, for the following activities/items: consulting: J‐YR, SA, MG, SLS, CCh, MKD, CCo, DF, PDD, PDM; research grants: J‐YR, MG, SLS, MKD, DF, PDM; attending symposia: J‐YR, SA, JJS, MKD, CCo, DF, PDD; giving lectures: J‐YR, SA, MG, SLS, MKD, RE, CCo, DF, PDD; funds for a member of staff: JJS; organising educational programmes: DF. LR, NM, BB are employees of Hoffmann‐La Roche Ltd. PL has no competing interests.

References

    1. Melton L J, Chrischilles E A, Cooper C, Lane A W, Riggs B L. Perspective. How many women have osteoporosis? J Bone Miner Res 199271005–1010. - PubMed
    1. International Osteoporosis Foundation Osteoporosis in the European community: action plan. International Osteoporosis Foundation, 2003. Available from, http://www.osteofound.org/advocacy_policy/eu_policy_project/pdf/action_p... (accessed 12 January 2006)
    1. Melton L J. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003181139–1141. - PubMed
    1. Chesnut C H, Skag A, Christiansen C, Recker R, Stakkestad J A, Hoiseth A.et al Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004191241–1249. - PubMed
    1. Delmas P D, Recker R R, Chesnut C H, Skag A, Stakkestad J A, Emkey R.et al Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 200415792–798. - PubMed

Publication types

MeSH terms